Zepbound denied by insurance: what to do next

Read the reason on the denial letter first. It tells you which of the routes below applies: a job-based or individual plan appeal, a Medicare Part D request, or a Medicare GLP-1 Bridge resubmission.

Last reviewed: October 23, 2026 · For readers in the United States

Disclosure: We sell the GLP-1 Appeal Kit. Money You're Owed makes it, and if you buy it we earn money. We don't take payment from anyone else mentioned here. This page is general information for US readers, not legal advice.

Start with the denial reason

The denial letter should name the reason and the rule behind it. For job-based and individual plans, the letter must give the specific reason, the plan provision it relies on, and what extra information would complete the claim. If the plan used an internal rule or criterion, the letter must include it or say you can get it free of charge. Match the reason to one of the sections below.

What Zepbound is approved for

The FDA approved Zepbound for adults with obesity, or with overweight and at least one weight-related condition, on November 8, 2023. On December 20, 2024 it approved Zepbound for moderate to severe obstructive sleep apnea (OSA) in adults with obesity, which the FDA called "the first drug treatment option for certain patients with obstructive sleep apnea".

The current label says Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity “to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition”, and "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity." If you appeal, quote the indication that matches your prescription.

Denied because your plan excludes weight-loss drugs

A written benefit exclusion is different from a medical-necessity denial. Ask for the exact plan provision the denial relies on, and check whether it applies to the use your prescriber wrote. Your appeal rights are set out in the free appeal letter sample.

Denied at prior authorization

The plan says something it requires was missing or not met. Compare each criterion in the denial with your records and your prescriber's request, then appeal with the missing records attached. Use the free appeal letter sample for a job-based or individual plan.

Denied for step therapy

The plan wants another drug tried first. Your appeal should list the prior therapies you have tried, with dates, exactly as your records show them. The deadlines and rights are the same as in the appeal letter sample.

Formulary change: CVS Caremark

CVS Caremark added Zepbound back to its commercial formularies as an additional preferred option on October 1, 2026. Caremark's October 2026 template formularies list both Wegovy (including Wegovy HD) and Zepbound under "Antiobesity".

From 1 July 2025 to 30 September 2026, Caremark's main commercial formularies dropped Zepbound in favour of Wegovy. From 1 October 2026 Caremark lists Zepbound again as a preferred option, but your plan may still exclude weight-loss drugs.

Being listed on Caremark's formulary doesn't guarantee your plan covers it. Caremark's own list says it "does not guarantee coverage", and plan sponsors that use Caremark's template formularies can customize coverage. If your denial came before October 1, 2026, or cites a plan exclusion, read the reason on the letter before you resubmit.

Denied for sleep apnea (OSA) coverage

Zepbound's label includes moderate to severe OSA in adults with obesity. If you are on Medicare, see the next section: CMS says this use can be covered under Part D through the plan's formulary-exception process. For a job-based or individual plan, appeal with the OSA indication quoted from the label.

Denied by Medicare

The weight-loss exclusion. By law, Part D can't cover drugs when used for weight loss (42 U.S.C. 1395w-102(e)(2)(A), which points to 42 U.S.C. 1396r-8(d)(2)(A): "Agents when used for anorexia, weight loss, or weight gain."). CMS did not finalize its proposal to cover anti-obesity drugs for obesity in its final rule of April 4, 2025.
Sleep apnea is different. CMS says Zepbound for moderate to severe OSA in adults with obesity is a use coverable under basic Part D, even if it isn't on the plan's formulary. Part D plans must handle these requests through their formulary-exception process.
The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027, at $50 a month Medicare copay, and covers Foundayo, Wegovy and Zepbound KwikPen only. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease aren't eligible for the Bridge and go through their Part D plan instead.
A Bridge prior-authorization denial has no appeals process; the prescriber can resubmit. Your Part D appeal rights, including exception requests, don't change.

Part D steps, in order

Coverage determination (the first decision, including an exception request): a coverage determination is due within 72 hours, or within 24 hours for an expedited request. For an exception, the clock starts when the plan receives your prescriber's supporting statement.
Redetermination (appeal level 1): file within 60 days of receiving the notice. Receipt is presumed 5 days after the notice date, so in effect you have 65 days from the date on the notice. The plan decides in 7 days for a drug request, 14 days for a payment request, or 72 hours if expedited.
Independent Review Entity (level 2): file within 60 days of the redetermination decision.
Levels 3 to 5: an Administrative Law Judge hearing (2026 threshold: $200 in dispute), the Medicare Appeals Council, then federal court (2026 dollar minimum ($1,960), with a 60-day filing window after the Appeals Council decision).

Which appeal route applies

Your coverage	Route
Job-based or individual plan	Internal appeal, then external review. See the free appeal letter sample and the appeal ladder.
Medicare Part D (for example, Zepbound for OSA)	Coverage determination or exception request, then redetermination and the later levels above.
Medicare GLP-1 Bridge	No appeals process. The prescriber can resubmit with corrected or additional information.

More detail: how to appeal a GLP-1 denial · free GLP-1 denial checklist.

Frequently asked questions

Does CVS Caremark cover Zepbound now?

Can Medicare Part D cover Zepbound for sleep apnea?

Yes, it can. CMS says Zepbound for moderate to severe obstructive sleep apnea in adults with obesity is a use coverable under basic Part D, even if the drug isn't on the plan's formulary, through the plan's formulary-exception process.

Can I appeal a Medicare GLP-1 Bridge denial?

No. CMS says there is no appeals process under the Medicare GLP-1 Bridge; the prescriber can resubmit the prior authorization. Your separate Part D appeal rights don't change.

How long do I have to appeal a Part D denial?

Ask your plan for a redetermination within 65 days from the date on the denial notice. The rule is 60 days from receiving the notice, and receipt is presumed 5 days after the notice date.